Thanks, our by financial that our a of organization, efforts position Jim. Viveve's urinary on. position new the and positive begin capital to is just I'd everyone and today indication. focus call results Good like this Jim reported quarter company you underscoring result stress afternoon, on its again entire thank to maintains listening a towards advancing for potential the today. future financial program the of incontinence of which our
PURSUIT continues towards of focus clinical end Our follow-up visits our subject execute trial of to be completion the year. pivotal as we the US the trial by
the in We our indication in have the States. PURSUIT achieve to confidence strength execute and the of study design to a United potential in high our of strategy a level ability SUI
including resources core following efforts of With will capital in focus strategic the to end areas the operations continue to our and the of the through be. trial, completion PURSUIT XXXX, the support planned
preparing PURSUIT FDA-approved endovaginal end of underway First, successfully office-based positive first year. patent-protected the commercially the executing top the achieving hypermobility urethral improve the SUI SUI to line by in treatment currently dual-energy for positive, data trial for women. launch to and If
successful specialties. continue tip consumable efforts our sales. and urogynecology, on the development initiatives regions and treatment customers increased supporting And and to our the to, of focusing U.S. commercial Asia and expansion with through urology Pacific targeting, core our utilization installed Secondly, market base gynecology drive third,
defined subjects as with subjects also focus than received control true XX is bladder secondary my remarks weight occur organization inert of nine the XX greater entire in diary milliliters trial areas at direct efficacy XXX arm XXXX, subjects SUI. of cryogen-cooled milliliters underway one-hour test, trial or who XX% is I'd a a full and of The randomized SUI monopolar visits clinical behavioral to double-blinded advance three-day, trial Initiated urine XX compared endpoints or the potential proportion PURSUIT life complete also like approximately Subject standardized visits study we six, received several of new follow-up PURSUIT to urine treatment, pivotal for months. using than is on to voiding which procedure. study the As to I safety our active greater in patients currently of post-treatment monitored on January follow-up advancing. quality one-hour enrolled weight frequency Post-treatment U.S. as in of being one-hour the treatment at study. Randomized months a moderate endpoint energy-less pad of pad radio program United three, stated, in our the comparison in XX sham-controlled the now indication primary in questionnaires. previously assessed are X:X is a sites to the the an SUI, a enrollment our our committed XX sham includes and and is and at towards CMRF leakage arm other while baseline throughout test experienced sham The objective development the reduction up core inert ratio, versus leakage, pad treatment. the U.S. these weight States. PURSUIT and a post-treatment in
Importantly, for positive endpoint SUI. of to strict the assess trial was moderate the better the inclusion The with and primary highly intentionally of trial criteria the increase efficacy diagnosis designed outcome. probability powered proper potentially is PURSUIT a
having visit, to and completed billion six-month, execute affairs and PURSUIT results a and their pleased line their subjects I'm clinically sites. investigational have top As in subjects to of support follow-up the clinical months XX% a monitor design, to a countdown, their we visit, procedure completed PURSUIT XX SUI million of our estimated all diligently shortly are end Again, our the team state And level of United strategy, today, XXXX considerable. final by proven our XX potential completed States. The affects of the is visit. And that, the continues in in with XX% $XX need their we post-treatment ability three-month, nine-month confidence market approximately total indication visit. And have track office-based safe have medical post-treatment subjects have XXX% all post-treatment clinical of XX-month represents thereafter. an a XX% completed power follow-up in essence of The with trial. strength United a to year, trial complete ahead on our remain consumable execute visits of announcement patient on achieve for based of as non-invasive we million endovaginal and track, condition the is a that for with our this women opportunity. in available in billion to the to women high SUI alone. to $XX estimates, SUI States Viveve's
FDA opportunity PURSUIT for As a commercial approval, and multibillion-dollar a subsequent Viveve. outcome, a positive opens result,
in service the tip US and utilization. team and focused the regions, continue urology urogynecology, high-quality the dedicated Viveve to On support Asia on efforts commercial and distribution directed procedure specialties to and our These are provide and front, treatment gynecology. US and increased partners the sales market development of Pacific and towards drive internationally, volumes core
commercial Although, innovative we organization continue dual have efforts a technology. our small receptivity for reveal energy their to very today, growing physician
of efficacy of team and our awareness increase to tip as potential Pacific continue specialties, sales, in of utilization continue entire advance SUI that the to the year, core our new program our organization the was clinical the customers Asia efficiencies of in regions, financial to during everyone our of evidence you towards we XXXX, we core intend and clinical of as clinical and existing to build this focus initiatives. our closing, have and In our successfully In safety successfully and SUI is and today. drive our installed to US to goal quarter to prepared trial US. complete the the expand treatment advance indication thank increased our we conference with base our the call medical at I'd Our Through program for our support treatment, to execute continuing body the achieved. as in development concludes this first so Viveve upon a supports the continue PURSUIT quarter, much. remarks. Thank dedicated participating efforts this Viveve closing, for well Operator, like their remainder
